MAP Pharmaceuticals, which develops inhalable drugs to treat migraine and pediatric asthma, filed terms Thursday with the SEC for its upcoming IPO. The firm plans to offer 5 million shares at a price range of $14 to $16 per share. Merrill Lynch and Morgan Stanley are joint book runners on the deal.
